John Mascarenhas, MD, discusses the rationale, mechanism, and design of the phase 1 INCA33989-101 and -102 trials investigating a CAL-R–targeted antibody for patients with essential thrombocythemia.

Researchers from The University of Osaka find that a protein expressed on malaria-infected red blood cells both hides it from ...